Cancer Cell: IL-15可能是慢性炎症致癌的重要机制

2012-11-16 Guido Marcucci 《癌症细胞》

  近日,刊登在《癌症细胞》期刊上的一项新研究显示,人体制造的一种类似于激素的促进炎症的物质,在处于高水平的时候,可能会导致一种恶性白血病。   虽然,人们知道诸如晒伤等慢性炎症有时候可能导致癌症,但是一直不清楚其背后的机理是什么。美国俄亥俄州立大学综合癌症中心,Arthur G. James癌症医院(OSUCCC-James)和Richard J. So

  近日,刊登在《癌症细胞》期刊上的一项新研究显示,人体制造的一种类似于激素的促进炎症的物质,在处于高水平的时候,可能会导致一种恶性白血病。

  虽然,人们知道诸如晒伤等慢性炎症有时候可能导致癌症,但是一直不清楚其背后的机理是什么。美国俄亥俄州立大学综合癌症中心,Arthur G. James癌症医院(OSUCCC-James)和Richard J. Solove研究所的科研人员发现,高水平的白细胞介素15(IL-15)可以在动物模型中导致大颗粒淋巴细胞(LGL)白血病—— 一种罕见的而且常常致命的癌症。

  通常,人体内释放白细胞介素15能刺激天然“杀手”细胞——破坏癌细胞和被病毒感染细胞的免疫细胞——的发育、生存和增殖。但是,当白细胞介素15在体内长期以高数量存在的时候——诸如在慢性炎症期间——它可能导致大颗粒淋巴细胞的特定免疫细胞变成癌细胞。

  研究人员表示,白细胞介素15与正常的大颗粒淋巴细胞表面上的受体结合时,会提升细胞内部的致癌蛋白质的水平。高致癌蛋白质水平反过来会带来染色体不稳定和额外的基因突变,还会激活一个称为DNA甲基化的过程,这个过程会关闭一批基因,包括通常会抑制肿瘤生长的重要基因。

  与此同时,这组科研人员还开发出了针对这种白血病的疗法。他们研究出了一种蛋白酶体抑制剂硼替佐米的脂质体剂型,它能关闭致癌路径,有可能治愈这种恶性疾病。实验中,接受这种脂质体硼替佐米治疗的白血病小鼠在130天里表现出了100%的存活率,而对照组的动物在60~80天里表现出了100%的死亡率。并且这一疗法在动物模型中没有表现出可辨别的副作用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2003303, encodeId=3930200330316, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9635, encryptionId=7fc0963527, topicName=IL-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Mar 30 22:08:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780594, encodeId=b1341e80594ed, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 11 22:08:00 CST 2012, time=2012-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868601, encodeId=919718686010d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 11 20:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958834, encodeId=a494195883411, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 30 09:08:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370770, encodeId=942b13e07705f, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508157, encodeId=29cb150815eed, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
    2013-03-30 wetgdt
  2. [GetPortalCommentsPageByObjectIdResponse(id=2003303, encodeId=3930200330316, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9635, encryptionId=7fc0963527, topicName=IL-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Mar 30 22:08:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780594, encodeId=b1341e80594ed, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 11 22:08:00 CST 2012, time=2012-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868601, encodeId=919718686010d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 11 20:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958834, encodeId=a494195883411, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 30 09:08:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370770, encodeId=942b13e07705f, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508157, encodeId=29cb150815eed, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2003303, encodeId=3930200330316, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9635, encryptionId=7fc0963527, topicName=IL-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Mar 30 22:08:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780594, encodeId=b1341e80594ed, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 11 22:08:00 CST 2012, time=2012-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868601, encodeId=919718686010d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 11 20:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958834, encodeId=a494195883411, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 30 09:08:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370770, encodeId=942b13e07705f, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508157, encodeId=29cb150815eed, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2003303, encodeId=3930200330316, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9635, encryptionId=7fc0963527, topicName=IL-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Mar 30 22:08:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780594, encodeId=b1341e80594ed, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 11 22:08:00 CST 2012, time=2012-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868601, encodeId=919718686010d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 11 20:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958834, encodeId=a494195883411, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 30 09:08:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370770, encodeId=942b13e07705f, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508157, encodeId=29cb150815eed, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
    2012-12-30 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=2003303, encodeId=3930200330316, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9635, encryptionId=7fc0963527, topicName=IL-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Mar 30 22:08:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780594, encodeId=b1341e80594ed, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 11 22:08:00 CST 2012, time=2012-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868601, encodeId=919718686010d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 11 20:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958834, encodeId=a494195883411, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 30 09:08:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370770, encodeId=942b13e07705f, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508157, encodeId=29cb150815eed, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
    2012-11-18 jambiya
  6. [GetPortalCommentsPageByObjectIdResponse(id=2003303, encodeId=3930200330316, content=<a href='/topic/show?id=7fc0963527' target=_blank style='color:#2F92EE;'>#IL-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9635, encryptionId=7fc0963527, topicName=IL-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Mar 30 22:08:00 CST 2013, time=2013-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780594, encodeId=b1341e80594ed, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 11 22:08:00 CST 2012, time=2012-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868601, encodeId=919718686010d, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 11 20:08:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958834, encodeId=a494195883411, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 30 09:08:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1370770, encodeId=942b13e07705f, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508157, encodeId=29cb150815eed, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Sun Nov 18 06:08:00 CST 2012, time=2012-11-18, status=1, ipAttribution=)]
    2012-11-18 jjjiang0202

相关资讯

美揭示慢性炎症致癌机制

  诸如晒伤等慢性炎症有时候可能导致癌症,但是仍然不清楚这是如何发生的。该研究首次揭示出了人体制造的一种促进炎症的物质如何能够导致一种恶性白血病这种知识可以让科研人员开发出治疗白血病的一种可能的疗法。   俄亥俄州哥伦布——由美国俄亥俄州立大学综合癌症中心- Arthur G. James癌症医院(OSUCCC – James)和Richard&

PNAS:揭秘感染如何致癌

       来自麻省理工学院的一项新研究提供了关于炎症进展至癌症过程中发生的化学和遗传改变的综合视图。       肝癌、结肠癌或胃癌最大的风险因子之一就是这些器官的慢性炎症,通常是由于病毒或细菌感染引起。麻省理工学院的一项新研究提供了关于这样的感染如何刺激组织发生癌变的最广泛